Skip to main content

Inhibition of PI3Kδ Improves Systemic Lupus in Mice

Inflammation volume 37, pages 978–983 (2014)Cite this article

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease accompanying excessive inflammatory responses. Phosphoinositide 3-kinase p110δ (PI3Kδ) is reported to associate with autoimmune conditions. We here aimed to determine whether selective inhibition of PI3Kδ is effective in a lupus model of BXSB mice, using the selective PI3Kδ inhibitor IC87114, which was intraperitoneally administrated to BXSB mice aged from 14 to 22 weeks. We showed that IC87114 improved renal function by decreasing the levels of proteinuria and serum creatinine, ameliorating the pathologic changes of kidneys and IgG and C3 deposition. Serum anti-autoantibody to nuclear antigen, anti-dsDNA, IL-1β, and IL-17 were markedly reduced by IC87114 therapy. Hepatic damage was also inhibited by administration of IC87114. Expression of phosphorylated AKT (p-AKT) and monocyte chemoattractant protein-1 was inhibited and mouse survival improved. In sum, PI3Kδ activation may be a critical factor for escalating autoimmune renal and hepatic damage, and its inhibition may alleviate the autoimmune damage. Our study reveals that the selective blockade of PI3Kδ is effective for mouse SLE.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

REFERENCES

  1. Gaitonde, S., D. Samols, and I. Kushner. 2008. C-reactive protein and systemic lupus erythematosus. Arthritis and Rheumatism 59: 1814–1820.

    CAS  PubMed  Article  Google Scholar 

  2. Costenbader, K.H., A. Desai, G.S. Alarcón, L.T. Hiraki, T. Shaykevich, M.A. Brookhart, et al. 2011. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis and Rheumatism 63: 1681–1688.

    PubMed Central  PubMed  Article  Google Scholar 

  3. Merrill, J.T., E.M. Ginzler, D.J. Wallace, J.D. McKay, J.R. Lisse, C. Aranow, et al. 2012. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis and Rheumatism 64: 3364–3373.

    CAS  PubMed  Article  Google Scholar 

  4. Yanaba, K., J.D. Bouaziz, T. Matsushita, C.M. Magro, E.W. St Clair, and T.F. Tedder. 2008. B- lymphocyte contributions to human autoimmune disease. Immunology Reviews 223: 284–299.

    CAS  Article  Google Scholar 

  5. Puri, K.D., and M.R. Gold. 2012. Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. Frontiers in Immunology 3: 256.

    PubMed Central  PubMed  Article  Google Scholar 

  6. Randis, T.M., K.D. Puri, H. Zhou, and T.G. Diacovo. 2008. Role of PI3Kdelta and PI3Kgamma in inflammatory arthritis and tissue localization of neutrophils. European Journal of Immunology 38: 1215–1224.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  7. Park, S.J., K.S. Lee, S.R. Kim, K.H. Min, H. Moon, M.H. Lee, et al. 2010. Phosphoinositide 3-kinase delta inhibitor suppresses interleukin-17 expression in a murine asthma model. European Respiratory Journal 36: 1448–1459.

    CAS  PubMed  Article  Google Scholar 

  8. Haylock-Jacobs, S., I. Comerford, M. Bunting, E. Kara, S. Townley, M. Klingler-Hoffmann, et al. 2011. PI3Kdelta drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation. Journal of Autoimmunity 36: 278–287.

    CAS  PubMed  Article  Google Scholar 

  9. Durand, C.A., M.J. Richer, K. Brenker, M. Graves, I. Shanina, K. Choi, et al. 2013. Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice. Autoimmunity 46: 62–73.

    CAS  PubMed  Article  Google Scholar 

  10. Kang, B.N., S.G. Ha, X.N. Ge, M. Reza Hosseinkhani, N.S. Bahaie, Y. Greenberg, et al. 2012. The p110δ subunit of PI3K regulates bone marrow-derived eosinophil trafficking and airway eosinophilia in allergen-challenged mice. American Journal of Physiology - Lung Cellular and Molecular Physiology 302: L1179–L1191.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  11. Sekine, H., K.L. Graham, S. Zhao, M.K. Elliott, P. Ruiz, P.J. Utz, et al. 2006. Role of MHC-linked genes in autoantigen selection and renal disease in a murine model of systemic lupus erythematosus. Journal of Immunology 177: 7423–7434.

    CAS  Article  Google Scholar 

  12. Arefieva, T.I., N.B. Kukhtina, O.A. Antonova, and T.L. Krasnikova. 2005. MCP-1-stimulated chemotaxis of monocytic and endothelial cells is dependent on activation of different signaling cascades. Cytokine 31: 439–446.

    CAS  PubMed  Article  Google Scholar 

  13. Zeng, G., F.H. Nystrom, L.V. Ravichandran, L.N. Cong, M. Kirby, H. Mostowski, et al. 2000. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101: 1539–1545.

    CAS  PubMed  Article  Google Scholar 

  14. Markopoulou, A., and V.C. Kyttaris. 2013. Small molecules in the treatment of systemic lupus erythematosus. Clinical Immunology 148: 359–368.

    CAS  PubMed  Article  Google Scholar 

  15. Fung-Leung, W.P. 2011. Phosphoinositide 3-kinase delta (PI3Kδ) in leukocyte signaling and function. Cellular Signalling 23: 603–608.

    CAS  PubMed  Article  Google Scholar 

  16. Puri, K.D., T.A. Doggett, J. Douangpanya, Y. Hou, W.T. Tino, T. Wilson, et al. 2004. Mechanisms and implications of phosphoinositide 3-kinase delta in promoting neutrophil trafficking into inflamed tissue. Blood 103: 3448–3456.

    CAS  PubMed  Article  Google Scholar 

  17. Ali, K., M. Camps, W.P. Pearce, H. Ji, T. Rückle, N. Kuehn, et al. 2008. Isoform-specific functions of phosphoinositide 3-kinases: p110 delta but not p110 gamma promotes optimal allergic responses in vivo. Journal of Immunology 180: 2538–2544.

    CAS  Article  Google Scholar 

  18. Okkenhaug, K., D.T. Patton, A. Bilancio, F. Garçon, W.C. Rowan, and B. Vanhaesebroeck. 2006. The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. Journal of Immunology 177: 5122–5128.

    CAS  Article  Google Scholar 

  19. Soond, D.R., E. Bjørgo, K. Moltu, V.Q. Dale, D.T. Patton, K.M. Torgersen, et al. 2010. PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood 115: 2203–2213.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  20. Ambrosi, A., A. Espinosa, and M. Wahren-Herlenius. 2012. IL-17: a new actor in IFN-driven systemic autoimmune diseases. European Journal of Immunology 42: 2274–2284.

    CAS  PubMed  Article  Google Scholar 

  21. Suárez-Fueyo, A., D.F. Barber, J. Martínez-Ara, A.C. Zea-Mendoza, and A.C. Carrera. 2011. Enhanced phosphoinositide 3-kinase δ activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death. Journal of Immunology 187: 2376–2385.

    Article  Google Scholar 

  22. Badr, G., H. Saad, H. Waly, K. Hassan, H. Abdel-Tawab, I.M. Alhazza, et al. 2010. Type I interferon (IFN-alpha/beta) rescues B-lymphocytes from apoptosis via PI3Kdelta/Akt, Rho-A, NFkappaB and Bcl-2/Bcl(XL). Cellular Immunology 263: 31–40.

    CAS  PubMed  Article  Google Scholar 

  23. Thacker, S.G., W. Zhao, C.K. Smith, W. Luo, H. Wang, A. Vivekanandan-Giri, B.J. Rabquer, A.E. Koch, S. Pennathur, A. Davidson, D.T. Eitzman, and M.J. Kaplan. 2012. Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis and Rheumatism 64: 2975–2985.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  24. Baccala, R., R. Gonzalez-Quintial, R.D. Schreiber, B.R. Lawson, D.H. Kono, and A.N. Theofilopoulos. 2012. Anti-IFN-α/β receptor antibody treatment ameliorates disease in lupus-predisposed mice. Journal of Immunology 189: 5976–5984.

    CAS  Article  Google Scholar 

  25. Ramanujam, M., P. Kahn, W. Huang, H. Tao, M.P. Madaio, S.M. Factor, et al. 2009. Interferon-alpha treatment of female (NZW x BXSB)F(1) mice mimics some but not all features associated with the Yaa mutation. Arthritis and Rheumatism 60: 1096–1101.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

Download references

Conflict of Interest

All authors declare no conflicts of interest.

Author information

Affiliations

  1. Department of Nephrology, General Hospital of Jinan Military Command, Jinan, 250031, China

    Yanxia Wang, Lei Zhang & Ping Wei

  2. Department of Nephrology, Zouping Hospital of Traditional Chinese Medicine, Zouping, 256200, China

    Huailiang Zhang

  3. Department of Dermatology, General Hospital of Jinan Military Command, No. 25 Shifan Road, Jinan, 250031, Shandong, China

    Cuijie Liu

Authors
  1. Yanxia Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ping Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Huailiang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cuijie Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cuijie Liu.

Additional information

Yanxia Wang and Lei Zhang contributed equally to this study.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wang, Y., Zhang, L., Wei, P. et al. Inhibition of PI3Kδ Improves Systemic Lupus in Mice. Inflammation 37, 978–983 (2014). https://doi.org/10.1007/s10753-014-9818-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10753-014-9818-0

KEY WORDS

  • systemic lupus erythematosus
  • phosphoinositide 3-kinase
  • p110δ
  • organ damage
  • BXSB mice